**PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC**

D. Raben,1 C. Faivre-Finn,2 D. Spigel,3 D. Daniel,3,4 A. Villegas,5 D. Vincente,6 R. Hui,7 J. de Castro Carpeno,8 S. Murakami,9 L. Paz-Ares,10 M. Özgüroḡlu,11 T. Kurata,12 A. Chiappori,13 K.H. Lee,14 M. de Wit,15 L. Poole,16 C. Wadsworth,17 P.A. Dennis,18 and S.J. Antonia13;

*1University of Colorado Cancer Center, Aurora, CO, 2Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom, 3Sarah Cannon Research Institute, Nashville, TN, 4Tennessee Oncology, Chattanooga, TN, 5Cancer Specialists of North Florida, Jacksonville, FL,*

*6Hospital Universitario Virgen Macarena, Sevilla, Spain, 7Westmead Hospital and the University of Sydney, Sydney, Australia, 8Hospital Universitario La Paz, Madrid, Spain, 9Kanagawa Cancer Center, Yokohama, Japan, 10Hospital Universitario 12 de Octubre, CiberOnc, Universidad Complutense and CNIO, Madrid, Spain, 11Istanbul University - Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey, 12Kansai Medical University Hospital, Hirakata, Japan, 13H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 14Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea, Republic of (South), 15Vivantes Klinikum Neukoelln, Berlin, Germany, 16AstraZeneca, Cambridge, United Kingdom, 17AstraZeneca, Alderley Park, United Kingdom, 18AstraZeneca, Gaithersburg, MD*

**Purpose/Objective(s):** In the global, Phase 3 PACIFIC study (Antonia 2017; NCT02125461), durvalumab significantly improved progressionfree survival (PFS) versus placebo in Stage III, unresectable NSCLC patients without progression after concurrent chemoradiotherapy (CRT) (stratified HR, 0.52; 95% CI, 0.42-0.65; P<0.001). This was the first major advance in this disease setting for many years. Here we report the second primary endpoint of overall survival (OS) for

PACIFIC.

**Materials/Methods:** Patients (any PD-L1 tumor status) with WHO PS 0/1 who received ≥2 cycles of platinum-based CRT were randomized (2:1) 1-42 days post-CRT to durvalumab 10 mg/kg IV Q2Wor placebo up to 12 months, stratified by age, sex, and smoking history. Primary endpoints were PFS from randomization (blinded independent central review; RECIST v1.1) and OS (interim analysis reported). Secondary endpoints included time to death or distant metastasis (TTDM) and PFS2 (time to second progression) from randomization and safety. Time to first/second subsequent therapy or death (TFST/TSST) were supportive assessments for PFS/PFS2.

**Results:** Between May 2014 and April 2016, 713 patients were randomized; 709 received treatment (durvalumab, n=473; placebo, n=236). As of March 22, 2018 (data cutoff), median follow-up duration was 25.2 months (range, 0.2-43.1). After discontinuation, 41.0% and 54.0% in the durvalumab and placebo groups received subsequent anticancer therapy; overall, 8.0% and 22.4% received additional immunotherapy. Durvalumab significantly improved OS versus placebo (stratified HR 0.68, 99.73% CI, 0.469-0.997; P=0.00251), with the median not reached (NR; 95% CI, 34.7 months-NR) and 28.7 months (95% CI, 22.9-NR), respectively. Durvalumab improved OS in all prespecified subgroups. Updated PFS remained similar (stratified HR 0.51, 95% CI, 0.41e0.63), with medians of 17.2 and 5.6 months with durvalumab

and placebo, respectively. Durvalumab improved updated TTDM (stratified HR 0.53, 95% CI, 0.41-0.68), and PFS2 (stratified HR 0.58, 95% CI, 0.46-0.73), TFST (stratified HR 0.58, 95% CI,

0.47-0.72) and TSST (stratified HR 0.63, 95% CI, 0.50-0.79). Within the durvalumab and placebo groups, 30.5% and 26.1% had grade 3/4 any-causality AEs, 15.4% and 9.8% discontinued due to AEs, and no new safety signals were identified; any-grade (grade 3/4) pneumonitis/radiation pneumonitis occurred in 33.9% (3.6%) and 24.8% (3.0%). Exploratory analyses characterizing outcome based on features of previous CRT will be presented.

**Conclusion:** Durvalumab demonstrated statistically significant and clinically meaningful improvement in OS compared with placebo, supported by secondary endpoints such as PFS2. PACIFIC is the first study to show a survival advantage following CRT in this locally advanced NSCLC population,

providing compelling evidence for the unprecedented benefit of durvalumab treatment as the standard of care.